Release date: 2025-04-10 10:45:12 Article From: Lucius Laos Recommended: 285
Understanding drug-drug interactions is critical to rational drug use.
Crizotinib is used as a drug for the treatment of specific conditions, and its metabolic processes are susceptible to other substances.
CYP3A4 enzyme modulators may alter blood levels of crizotinib. Ritonavir-containing antivirals increase crizotinib bioavailability by up to 40%, while antiepileptic drugs such as phenytoin may lower blood levels below the therapeutic threshold.
Proton pump inhibitors and H2 receptor antagonists need to be given at intervals. Concomitant administration of omeprazole and crizotinib may reduce the absorption rate of the latter by 12% to 18%, and it is recommended to wait at least 4 hours between them.
St. John's wort extract reduces the efficacy of crizotinib by 28%. The furanocoumarin in grapefruit and its products may interfere with drug metabolism, and special caution should be taken when the daily intake exceeds 200g.
Treatment cost control requires comprehensive consideration of multi-dimensional factors.
The average monthly cost of the original drug is about $6,900, and the generic drug with quality certification can be reduced to $2,300-3,500. In some areas, the price difference can be as high as 62%, which needs to be obtained through formal channels.
Routine check-ups cost about $380-$520 per month. Liver function monitoring accounted for 18% of the total expenditure, and electrocardiogram (ECG) accounted for about 9% of the total expenditure.
Health insurance coverage can reduce direct expenditures by 45%-60%. The Pharmaceutical Companies Assistance Program can save those who qualify for $8,200 per year, and generic drug treatment programs can reduce annual costs by 34 percent.
Understanding the mechanism of drug interactions can help improve the precision of treatment, and combined with economic evaluation, the treatment plan can be optimized. It is recommended that patients establish a personalized medication management plan under the guidance of professionals.
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:2012024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended:1582025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended:1562025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended:1712024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended:1612024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended:1462024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended:1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended:2482024-26-08
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: